Recently, Beijing Yewei Medical Technology Co., Ltd. ("Yewei Medical") announced the completion of a nearly 100 million RMB equity financing round. This round was led by Fenix Capital, with participation from Beishang Capital and Bohai Chuangfu, and Kaicheng Capital serving as the exclusive financial advisor.

This marks Yewei Medical's second substantial financing round within the year, fully reflecting the capital market's strong recognition of the company's development trajectory. Supported by this financing, Yewei Medical will continue to comprehensively strengthen its R&D innovation and market penetration capabilities in cardiovascular surgery and other related fields, further solidifying its leading position.

Founded in September 2021 and headquartered in Beijing, Yewei Medical leverages its founding team's extensive clinical experience to identify clinical needs while assessing current industry dynamics. The company is developing multiple global-first, China-first, or market-gap-filling medical devices. Currently, it has two self-developed product lines — Coronary Surgery, and Critical Care & Cardiopulmonary Bypass — comprising nearly 10 products. Among these, the ultrasound vascular blood flow measurement system, pulsatile left ventricular assist system, and dual-lumen jugular vein cannula are all China-first products.

While deepening its core business and strengthening its competitive advantages, Yewei Medical possesses strong capabilities for business expansion and M&A integration. In 2025, through an acquisition, the company expanded into the DVT product line, which includes two innovative medical devices that have both entered the registrational clinical trial stage, further reinforcing its industry leadership.